Open Monoclonal Technology's Acquisition

Open Monoclonal Technology was acquired by Ligand Pharmaceuticals on December 17, 2015.

Open Monoclonal Technology (OMT) is a leader in genetic engineering of animals for the generation of monospecific, bispecific and polyspecific human therapeutic antibodies, as well as naturally optimi…

Articles about Open Monoclonal Technology's Acquisition: